This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayakawa, M. Articles by Irie, M. Search for Related Content PubMed PubMed Citation Articles by Hayakawa, M. Articles by Irie, M.

Metabolic Effects of 20-Kilodalton Human Growth Hormone (20K-hGH) for Adults with Growth Hormone Deficiency: Results of an Exploratory Uncontrolled Multicenter Clinical Trial of 20K-hGH

Research and Development Operations (M.H., Y.S.), Nihon Schering K.K., Osaka 532-0004; Department of Medicine 2 (T.T., K.T.), Tokyo Women’s Medical University, Tokyo 162-0054; Department of Medicine 2 (Y.K.), Shimane Medical School, Izumo 693-8501; Department of Internal Medicine 3 (K.C.), Kobe University Graduate School of Medicine, Kobe 650-0017; Clinical Research Institute (A.S.), Center for Endocrine and Metabolic Diseases, Kyoto National Hospital, Kyoto 612-8555; and Toho Medical School (M.I.), Toho University, Tokyo 143-8541, Japan

Address all correspondence and reprint requests to: Mr. Masakane Hayakawa, Project Management Department, R&D Operations, Nihon Schering K.K., 6-64, Nishimiyahara 2-chome, Yodogawa-ku, Osaka 532-0004, Japan. E-mail: mahayakawa{at}schering.co.jp.

The biological effects of 20-kDa human GH (20K-hGH), which is produced in the pituitary by alternative splicing of GH mRNA and comprises approximately 6% of all GH in serum, have not been reported.

We have investigated the metabolic effects of recombinant 20K-hGH in adult patients with GH deficiency in an exploratory study. Three doses of 20K-hGH (0.006, 0.012, and 0.024 mg/kg·d), were administered for 16 wk to three groups (consisting of 18 or 19 subjects), respectively. The 20K-hGH dose-dependently increased serum IGF-I and IGFBP-3 levels, and the lowest dose (0.006 mg/kg) was enough to normalize both hormones by wk 4. Serum osteocalcin levels and urinary deoxypyridinoline excretion were also dose-dependently increased. There was a significant decrease in body fat mass with an increase of lean body mass at the lowest dose of 0.006 mg/kg·d. Blood glucose and serum insulin were increased significantly at 4 wk only in the high-dose group (0.024 mg/kg). Glucose tolerance was slightly impaired in 26–39% of patients in all treatment groups as judged by oral glucose tolerance tests, but there was no development of overt diabetes. The major adverse event in the 20K-hGH treatment was peripheral edema, similar to the incidence reported for 22K-hGH.

The data demonstrated that 20K-hGH had metabolic effects comparable to those of 22K-hGH in humans. The results suggest that 20K-hGH could be used to treat GH-deficient patients, although further studies may be required to investigate the optimum dose and superiority of 20K-hGH over 22K-hGH in a comparative study.

Abbreviations: ALT, Alanine aminotransferase; ANP, atrial natriuretic peptide; AST, aspartate aminotransferase; BFM, body fat mass; BP, binding protein; Cho, cholesterol; CT, computed tomography; CV, coefficient(s) of variation; DL, detection limit(s); EF, ejection fraction; %FS, fractional shortening; GHD, GH deficiency or GH deficient; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; hGH, human GH; hGHR, human GH receptor(s); IGT, impaired glucose tolerance; IRMA, immunoradiometric assay(s); 20K-hGH, 20-kDa hGH; LBM, lean body mass; LDL, low-density lipoprotein; NEFA, nonesterified fatty acid; OGTT, oral glucose tolerance test; QOL, quality of life; V/S, visceral fat to sc fat ratio.

This article has been cited by other articles:

				M. H. Vickers, S. Gilmour, A. Gertler, B. H. Breier, K. Tunny, M. J. Waters, and P. D. Gluckman 20-kDa placental hGH-V has diminished diabetogenic and lactogenic activities compared with 22-kDa hGH-N while retaining antilipogenic activity Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E629 - E637. [Abstract] [Full Text] [PDF]

				M. Bidlingmaier Problems with GH assays and strategies toward standardization Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S41 - S44. [Abstract] [Full Text] [PDF]